Navigation Links
Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
Date:10/21/2008

by more moderate growth in

our SAFC business. Recent Research selling price increases are expected

to mitigate the impact of slowing pharmaceutical demand in both

Research and Fine Chemicals. Currency could add another 3% to 4% to

full year 2008 sales growth, but reduce otherwise reportable growth in

Q4 2008 by approximately 3%, if exchange rates remain at September 30,

2008 levels.

-- Improved Margins Expected: Currency, lower interest rates, our supply

chain initiative and other process improvements are expected to enhance

the pretax profit margin for full year 2008 from the 21.5% pretax

margin achieved in full year 2007.

-- EPS Guidance Reaffirmed: Management reaffirmed its full year 2008

diluted EPS expectation in the range of $2.62 to $2.72. Improved

margins and the recent reinstatement of the U.S. R&D tax credit

retroactive to January 1, 2008 should offset a lower expected Q4

currency benefit (based on September 30, 2008 currency rates) and the

anticipated impact from ongoing softness in pharmaceutical based sales.

-- Share Buyback Authorization Increased: An additional 10 million shares

were added to the prior authorization, indicating management's

confidence in its long-term growth potential and its ability to return

capital to shareholders.

CEO's STATEMENT:

Commenting on third quarter performance and future expectations, President and CEO Jai Nagarkatti said: "We are pleased with our performance as we continue to pursue and achieve above market growth. We're in the final quarter of our 2006-2008 strategic plan, with the initiatives that have been key to growth over that period still performing very well. And, we're now finalizing our plans to add new activities as we seek to drive growth above market rates for the next three years. Our organic growth has been at roughly
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program
2. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
3. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
4. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
5. Sigma-Aldrich to Present at the UBS 2008 Global Life Sciences Conference on September 24, 2008
6. Sigma-Aldrich Launches Breakthrough Genome-Editing Tools
7. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
8. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
9. Sigma-Aldrich (Nasdaq: SIAL) Reports 16.7% Gain in Q2 2008 Diluted EPS. Q2 2008 Sales Rise 14.4%. 2008 Diluted EPS Forecast Raised $.05 to $2.62-$2.72.
10. Sigma-Aldrich Corporations 2nd Quarter 2008 Earnings Conference Call
11. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for its Oral Amphotericin B program.  The company ... vitro work involving samples from HIV/AIDS patients ... complete pre clinical studies and regulatory filings to ... trial, utilizing approximately $700,000 of funding and technological ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
(Date:10/19/2014)... 19, 2014 The Latin American hardware ... in Latin America with analysis and forecast of revenue. ... and is expected to reach $2,366.8 million by 2018, ... , Browse through the TOC of the Latin American ... the in-depth analysis provided. It also provides a glimpse ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
... ... Intellectual Property, FULLERTON, Calif., Nov. 28 Beckman Coulter,Inc. ... and,automate complex biomedical testing announced today that it has entered,into an ... spin out of Lumigen, Inc., effected prior to Beckman,Coulter,s acquisition of ...
... Cambridge Research &,Instrumentation (CRi) announced today that ... of allowance for their patent application number,10/669,101, for ... patent covers the use of multispectral imaging combined,with ... of,fluorophores in a living mammal. The unmixing of ...
... 1-41 has significant ... and anti-amnesic benefits, GENEVA, Nov. 28 /PRNewswire-FirstCall/ - ... announce promising developments with,ANAVEX 1-41, the company,s lead drug ... 1-41 prevented oxidative stress,which damages and destroys cells and ...
Cached Biology Technology:Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies 2US Patent and Trademark Office Allows CRi's Patent Application for Spectral Imaging of Deep Tissue 2Anavex advances drug candidate for treatment of Alzheimer's disease 2Anavex advances drug candidate for treatment of Alzheimer's disease 3Anavex advances drug candidate for treatment of Alzheimer's disease 4Anavex advances drug candidate for treatment of Alzheimer's disease 5
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... leading edge technologies including Wocket™, the Smart Wallet, at ... Conferenece. FiRe is a leading global conference on the ... Hosted by Mark Anderson , founder and publisher ...
(Date:10/15/2014)... to an unexpected extent. The outbreak does not follow ... shows a new disease dynamic in regions, where it ... German National Academy of Sciences Leopoldina, acatech – the ... of the German Academies of Sciences and Humanities have ... In the statement the academies call for the following ...
(Date:10/14/2014)... prostate cancer tumors scavenge and hoard copper that is ... may be a fatal weakness. , Researchers at ... cancer cells by delivering a trove of copper along ... brimming with the mineral, leaving non-cancer cells healthy. , ... available for other uses, could soon be tested in ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2
... characterise their Zap-It! product, which uses the tiny electric ... itching caused by insect bites - such as those from ... that is based around a similar piezoelectric mechanism to that ... a medical device, currently available to buy in high street ...
... Molecular biologist Ichiro Matsumoto, Ph.D., of the Monell Center, ... Young Investigators in Gustation, awarded annually by the Association ... who is an emerging leader in the field of ... the understanding of the organization, relationships and connectivity of ...
... of the potentially deadly antibiotic-resistant bacterium known as MRSA ... a new study involving two Northern Arizona University researchers., ... for Microbial Genetics and Genomics, and Lance Price, NAU ... Microbiology and Environmental Health at the Translational Genomics Research ...
Cached Biology News:Zapping mosquito bites 2Evolution of staph 'superbug' traced between humans and food animals 2
...
...
Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
Biology Products: